May 27, 2010
The Question
What is the history of the Affordable Medicines Facility-malaria (AMFm), and how will it affect access to artemisinin-combination therapies (ACTs)?
What we found
AMFm is a platform that will efficiently supply ACTs at low prices, reducing the use of monotherapies and other less-effective antimalarials.
Why it matters
Without a subsidy, ACTs cost substantially more than other malaria treatments. AMFm will increase access to ACTs, which will in turn delay the development of artemisinin resistance.
